Projects
MOA
Indications
IND
Phase I
Phase II
Phase III
Rights
LK03
Protein-based Drugs
Metabolic Syndrome
Global
LK04
Nucleic Acid Drugs
Metabolic Syndrome
Global
LK01
Small-molecule Drugs
Metabolic Syndrome and Fibrosis
Global
LK02
Protein-based Drugs
Metabolic Syndrome
Global
LK05
Protein-based Drugs
Metabolic Syndrome and Fibrosis
Global
LK06
Nucleic Acid Drugs
Metabolic Syndrome
Global
LK07
Cell-based Drugs
Metabolic Syndrome
Global
LK08
Small-molecule Drugs
Metabolic Syndrome
Global
LK03Protein-based Drugs
IND
Phase I
Phase II
Phase III
MOA
Protein-based Drugs
Rights
Global
LK04Nucleic Acid Drugs
IND
Phase I
Phase II
Phase III
MOA
Nucleic Acid Drugs
Rights
Global
LK01Small-molecule Drugs
IND
Phase I
Phase II
Phase III
MOA
Small-molecule Drugs
Rights
Global
LK02Protein-based Drugs
IND
Phase I
Phase II
Phase III
MOA
Protein-based Drugs
Rights
Global
LK05Protein-based Drugs
IND
Phase I
Phase II
Phase III
MOA
Protein-based Drugs
Rights
Global
LK06Nucleic Acid Drugs
IND
Phase I
Phase II
Phase III
MOA
Nucleic Acid Drugs
Rights
Global
LK07Cell-based Drugs
IND
Phase I
Phase II
Phase III
MOA
Cell-based Drugs
Rights
Global
LK08Small-molecule Drugs
IND
Phase I
Phase II
Phase III
MOA
Small-molecule Drugs
Rights
Global